Allay Therapeutics

Allay Therapeutics is a clinical-stage biotechnology company developing ultra-sustained analgesic products to transform post-surgical pain management. Their core mission is to reduce opioid use and improve patient recovery by delivering extended pain relief within a targeted site over weeks using their proprietary technology platform. ATX101, their novel investigational analgesic, is designed to provide extended pain relief after surgery.

Funding Round: Series D & Venture Debt

Funding Amount: $57.5M

Date: 05-Jun-2025

Investors: Lightstone Ventures, ClavystBio, NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare, Brandon Capital, IPD Capital, EDBI, SGInnovate, Maruishi Pharmaceutical, HSBC Innovation Banking

Markets: Biotech, Healthcare

HQ: San Jose, California, United States

Founded: 2016

Website: http://www.allaytx.com/

LinkedIn: https://www.linkedin.com/company/allaytx

Twitter: https://twitter.com/allaytx

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/allay-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/466496-29